Kelsey Moody | Managing Partner
Mr. Moody is a process-oriented biotechnology executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, Mr. Moody has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated contract research organization that focuses on pre-clinical research services for aging pathways. Proceeds from this work are used to self-fund R&D initiatives that constitute Ichor’s portfolio companies in enzyme therapy (Lysoclear, Inc.), small molecule drug discovery (Antoxerene, Inc.), antibody mimetics (Auctus Biologics, Inc.), and protein chemistry tools (RecombiPure, Inc.). Mr. Moody has received graduate-level training in medicine, business, and laboratory research.
Aaron Wolfe | Managing Partner
Aaron Wolfe is COO at Ichor Therapeutics. In this role, he headed up co-development projects with Ichor’s p53/MDM2 and p53/FOXO4 drug discovery program (Antoxerene, Inc.) and macular degeneration enzyme therapy program (Lysoclear, Inc.). He is also a technical founder of the company’s antibody mimetic technology (Auctus Biologics, Inc.). Mr. Wolfe has expansive experience in establishing company objectives, identifying research trajectory and regulatory path, and developing IP strategy. He raised over $1.5M in equity financing for his start-up company, Finger Lakes Bio, before joining the Ichor family. Previously, Mr. Wolfe worked as a biotechnology consultant for RLH, LLC. He is a Ph.D. candidate in structural biology, biochemistry, and biophysics (SB3) at Syracuse University. Mr. Wolfe holds a certificate in entrepreneurship from the Wharton School and a BS in biotechnology from SUNY ESF.
Roger Bagg | Managing Partner
Roger Bagg is a self-made serial entrepreneur and angel investor. He has successfully grown multiple companies in diverse sectors from Electronics & Engineering to Biotechnology, from start-up phase, through to multi-million turnovers. He understands the need for early development of effective systems and processes within early life cycle ventures and the difficulties they face to scale. Mr. Bagg has been working as an investor/partner with Ichor Therapeutics, Inc. since 2014. He seed-funded and helped develop Ichor’s CRO and portfolio company ventures from the original living room start-up, to the industry beating position they currently enjoy within the burgeoning aging space.